Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q2 2025 Earnings Presentation
18 slides from Arcticzymes Technologies Asa's earnings presentation, Aug 14, 2025
Slide 1: Driving Sustainable, Profitable Growth Q2 2025
August 14, 2025 CEO Michael Akoh Driving Sustainable, Profitable CFO Børge Sørvoll Growth VP Sales Paul Blackburn Q2 2025
Slide 2: Overview
Overview Overview ADriving Norwegian biotechProfitable Sustainable, with growth Growth potential A provider of novel Customers are life World class products and Targeting segments with Worldclass Products enzymes for advanced therapies and molecular considerable growth Segment & Customers science to
Slide 3: Agenda
Agenda 1 Highlights Q2 & Strategic Priorities 2 Sales - Biomanufacturing and Molecular Tools 3 Financials 4 Outlook and Q&A
Slide 4: Highlights Q2 2025
Highlights Q2 2025 Total Biomanufacturing revenue up 5% M SAN HQ GMP growth accelerates 28.9 MNOK Launched June 16 18.1 MNOK +52% YoY (27.5 MNOK) +33% QoQ M SAN HQ most Increased diversified EBITDA sold product in Q2 customer portfolio – up 50% Growth of 62% vs not dependent on 3.9 MNOK Q2 LY single
Slide 5: Strategic priorities
Strategic priorities From Strong Fundamentals to Sustained Growth Short Term (2025 focus) Long Term (2026- ) 1 Customer Centric Transformation 1 Develop/commercialize new Molecular Tools enzymes Commercialization – build diversified customer base NGS Channel development through partners (CDMO/Distri
Slide 6: M-SAN HQ GMP
M-SAN HQ GMP Milestone Achieved: Launch of GMP- grade M-SAN - June 16th 2 Why it matters Enables use in late-stage and commercial biomanufacturing workflows Full regulatory documentation package Complements SAN neo HQ GMP => offering broader salt processing range and performance fit Commercial poten
Slide 7: Sales Update Q2 2025
Sales Update Q2 2025
Slide 8: Q2 Sales - Overview
Q2 Sales - Overview Biomanufacturing and Molecular Tools Sales combined 35 Total sales up slightly in Q2-2025 vs Q2-2024 30 (26.8 MNOK vs 26.5 MNOK, +1%) 25 Growth led by strong Biomanufacturing performance Sales in MNOK 20 15 Molecular Tools showing underlying momentum, with gains in Cod UNG and 10
Slide 9: Q2 Sales - Biomanufacturing
Q2 Sales - Biomanufacturing Steady Performance with Expanding Customer Base Sales per area 20 Strong Biomanufacturing sales at 18.1 MNOK GMP product versions continuing to gain 15 market traction Sales in MNOK Record quarter for M-SAN HQ, +62% vs 10 previous record (Q3-2023) 5 M-SAN HQ now the #1 se
Slide 10: Q2 Sales - Molecular Tools
Q2 Sales - Molecular Tools Underlying business intact Sales per area Revenue softness (8.7M NOK, -40%) in Q2 25 driven by absence of orders from one key customer which has now returned 20 USA sales up +70%, fuelled by strong rSAP 15 and Cod UNG momentum Sales in MNOK 10 EMEA down -75% due to non-rep
Slide 11: Customer Diversification
Customer Diversification Unique customers and Order Trends We had slightly fewer Unique Customers vs Q2-2024, driven by a decline in Molecular Tools customers Unique Segment Orders AOV Molecular Tools Q2 Customers Biomanufacturing -2.7% +4.3% +48.7% Molecular Tools -20.2% -20.5% -27.4%* Combined -10
Slide 12: Expenses & Profitability
Expenses & Profitability
Slide 13: Profit and loss, Expense development
Profit and loss, Expense development Change in spend as we transform Q2 YTD Personnel expenses 2025 2024 2025 2024 Sales revenues 26,8 26,5 50,0 56,5 Reduction Norwegian personnel Other revenues 2,1 1,0 3,8 1,1 Increase in intl. personnel Sum revenues 28,9 27,5 53,8 57,6 Reduced capitalisation Cost
Slide 14: Currency impact
USDNOK Currency impact 12 11,5 Slightly negative for the quarter 11 10,5 Majority of revenues are in foreign currency 10 63% in USD 9,5 36% in EURO 9 73% in USD and 27% in EURO for 2024 2024 2025 EURNOK Currency effect on P&L 12,2 Finance 12 Decrease of 0.5 MNOK in Q2 (-0.2 MNOK in Q2 11,8 2024) and
Slide 15: Profitability and expenses
Profitability and expenses Positive margin Sales & EBITDA Q2 YTD 2025 2024 2025 2024 Sales Sales revenues 26,8 26,5 50,0 56,5 35 EBITDA Other revenues 2,1 1,0 3,8 1,1 Sum revenues 28,9 27,5 53,8 57,6 30 25 Cost of materials -1,5 -1,5 -2,8 -2,5 Change in inventory 0,0 -0,6 0,3 -0,9 20 Personnel expen
Slide 16: Cash flow and short-term investments
Cash flow and short-term investments 4.2 MNOK in changes for Q2* Cash and STI position 280 30 Short term investments (STI) Net Cash (MNOK) Changes in Cash and STI (MNOK) 25 260 20 240 Changes in cash and STI (MNOK) 15 Net Cash (MNOK) 220 10 200 5 180 0 160 -5 140 -10 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Slide 17: Outlook 2025
Outlook 2025 The Opportunity • Continued biomanufacturing growth, particularly in the US • Recovery in Molecular Tools driven by incoming orders CDMO platform partnership • Gradual revenue contribution ramp-up • M-SAN GMP to drive long-term momentum and open new doors Market development • Focus on M
Slide 18: Thank you Q&A
Thank you Q&A arcticzymes.com
ArcticZymes Technologies — Q2 2025 Earnings Presentation on 6ix